Literature DB >> 10942168

Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts.

S Mital1, A Magneson, K E Loke, J Liao, P R Forfia, T H Hintze.   

Abstract

Statin drugs, which are cholesterol-lowering agents, can upregulate endothelial nitric oxide synthase (eNOS) in isolated endothelial cells independent of lipid lowering. We investigated the effect of short-term simvastatin administration on NO-mediated regulation of myocardial oxygen consumption (MV(O2)) in tissue from rat hearts. Male Wistar rats were divided into (a) control group (n = 14), and (b) simvastatin group (n = 10, 20 mg/kg/day by oral gavage). After 2 weeks, left ventricular myocardium was isolated to measure MV(O2) using a Clark-type oxygen electrode, and aortic plasma nitrates and nitrites (NOx) were measured. Baseline plasma NOx levels (19+/-2.6 in control vs. 20+/-2.5 microM/L in simvastatin) and baseline MV(O2) (288+/-23 in control vs. 252+/-11 nmol/g/min; p = 0.09) were not significantly different between the two groups. NO-dependent regulation of MV(O2) in response to bradykinin, ramipril, or amlodipine was augmented in simvastatin rats compared with controls (p < 0.05). Decrease of MV(O2) from baseline in response to highest doses in control versus simvastatin groups was as follows-bradykinin, -28+/-5% vs. -44+/-6%; ramipril, -35+/-5% vs. -50+/-8%; and amlodipine, -32+/-9% vs. -42+/-3%. Response to highest dose of NO donor S-nitroso N-acetyl penicillamine (SNAP) was not significantly different in the two groups (-55+/-5% vs. -52+/-7%). Treatment with Nw-nitro-L-arginine methyl ester, inhibitor of NO synthesis, attenuated the effect of bradykinin, ramipril, and amlodipine on MV(O2) (p < 0.05). In conclusion, short-term administration of simvastatin in rats potentiates the ability of angiotensin-converting enzyme (ACE) inhibitors and amlodipine to cause NO-mediated regulation of MV(O2).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942168     DOI: 10.1097/00005344-200008000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Bicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation.

Authors:  Nalini M Rajamannan
Journal:  Cardiovasc Pathol       Date:  2011-01-22       Impact factor: 2.185

2.  Simvastatin preserves cardiac function in genetically determined cardiomyopathy.

Authors:  Seena S Abraham; Juan C Osorio; Shunichi Homma; Jie Wang; Harshwardhan M Thaker; James K Liao; Seema Mital
Journal:  J Cardiovasc Pharmacol       Date:  2004-03       Impact factor: 3.105

3.  Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects.

Authors:  H Yasuda; P S T Yuen; X Hu; H Zhou; R A Star
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

4.  Preservation of NO production by statins in the treatment of heart failure.

Authors:  Jean-Noel Trochu; Seema Mital; Xiao ping Zhang; Xiaobin Xu; Manuel Ochoa; James K Liao; Fabio A Recchia; Thomas H Hintze
Journal:  Cardiovasc Res       Date:  2003-11-01       Impact factor: 10.787

5.  Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor.

Authors:  Juan C Osorio; Faisal H Cheema; Timothy P Martens; Naila Mahmut; Caroline Kinnear; Ana M D Gonzalez; William Bonney; Shunichi Homma; James K Liao; Seema Mital
Journal:  Can J Physiol Pharmacol       Date:  2008-09       Impact factor: 2.273

Review 6.  Acute and chronic endothelial dysfunction: implications for the development of heart failure.

Authors:  Axel Linke; Fabio Recchia; Xiaoping Zhang; Thomas H Hintze
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.